Cargando…
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene
Benign recurrent intrahepatic cholestasis (BRIC) is a group of genetically heterogeneous autosomal recessive liver disorders characterized by recurrent episodes of jaundice and pruritus. BRIC is divided into two groups, BRIC type 1 (BRIC1) and BRIC type 2 (BRIC2), caused by mutations in the ATP8B1 a...
Autores principales: | Miura, Ryoichi, Kawaoka, Tomokazu, Imamura, Michio, Kosaka, Masanari, Johira, Yusuke, Shirane, Yuki, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Ando, Yuwa, Kosaka, Yumi, Kodama, Kenichiro, Uchikawa, Shinsuke, Fujino, Hatsue, Ono, Atsushi, Nakahara, Takashi, Murakami, Eisuke, Yamauchi, Masami, Hinoi, Takao, Aikata, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958625/ https://www.ncbi.nlm.nih.gov/pubmed/35431768 http://dx.doi.org/10.1159/000522145 |
Ejemplares similares
-
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022) -
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022) -
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021) -
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment
por: Yamaoka, Kenji, et al.
Publicado: (2022) -
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
por: Johira, Yusuke, et al.
Publicado: (2023)